Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents by Aylward, Lesa L. et al.
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 2 | February 2010  177
Review
Biomonitoring data for 2,4-dichlorophenoxy-
acetic acid (2,4-D) in urine samples are now 
available from a number of studies of both 
the general population (including preschool-
age children) and farm applicators and their 
family members [Alexander BH, et al. 2007; 
Arbuckle and Ritter 2005; Arbuckle et al. 
2002, 2004, 2006; Centers for Disease Control 
and Prevention (CDC) 2005; Morgan et al. 
2008]. Such data provide an integrated meas-
ure of absorbed dose from all pathways and 
routes of exposure. The hazards of 2,4-D were 
recently assessed by the U.S. Environmental 
Protection Agency (U.S. EPA 2004) and 
the Canadian Pest Management Regulatory 
Agency (PMRA 2007). The U.S. EPA–derived 
reference doses (RfDs) for acute and chronic 
exposure to 2,4-D are based on external expo-
sure metrics (administered dose), which are 
not directly useful for evaluating biomonitor-
ing data. However, Biomonitoring Equivalent 
(BE) values corresponding to RfDs for acute 
and chronic exposure scenarios are now avail-
able (Aylward and Hays 2008) and can be 
used as a tool for assessing the biomonitor-
ing data directly in a public health risk assess-
ment context, without requiring calculation of 
corresponding external dose, as has previously 
been done (Mage et al. 2004). Here we review 
urinary biomonitoring data for 2,4-D from 
several studies in the general population and in 
farmers and farm family members and evalu-
ates the data in the context of the BE values for 
2,4-D presented by Aylward and Hays (2008) 
to assess the current margin of safety (ratio of 
exposure guidance value such as an RfD to 
exposure measures) for population exposures 
to 2,4-D in the United States and Canada.
Methods
Biomonitoring data.  We used urinary 
biomonitoring data for 2,4-D from several 
studies of both general population adults and 
children and from studies of farmers and farm 
family members, as follows.
The National Center for Environmental 
Health of the Centers for Disease Control 
and Prevention (CDC 2005) measured 2,4-D 
in urine samples collected from a complex, 
stratified random sample of the civilian, non-
institutionalized population of the United 
States, 6–59 years of age, during 2001–2002, 
as part of the National Health and Nutrition 
Examination Survey (NHANES).
Morgan et al. (2004, 2008) recently exam-
ined the exposures of 135 preschool children and 
their adult caregivers to 2,4-D at their homes in 
North Carolina and Ohio from the Children’s 
Total Exposure to Persistent Pesticides and 
Other Persistent Organic Pollutants (CTEPP) 
study. Participants were randomly recruited 
from homes in six North Carolina and six 
Ohio counties. Participants were recruited by 
field staff from homes between February 2000 
and February 2001 in North Carolina and 
January 2001 and November 2001 in Ohio. 
Monitoring was performed over a 48-hr period 
at the participants’ homes. Spot urine samples 
and environmental samples including air, soil, 
dust, hand wipes, and food were collected and 
analyzed for 2,4-D.
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ba c K g r O u n D: Several extensive studies of exposure to 2,4-dichlorophenoxyacetic acid (2,4-D) 
using urinary concentrations in samples from the general population, farm applicators, and farm 
family members are now available. Reference doses (RfDs) exist for 2,4-D, and Biomonitoring 
Equivalents (BEs; concentrations in urine or plasma that are consistent with those RfDs) for 2,4-D 
have recently been derived and published. 
Ob j e c t i v e: We reviewed the available biomonitoring data for 2,4-D from the United States and 
Canada and compared them with BE values to draw conclusions regarding the margin of safety for 
2,4-D exposures within each population group. 
Da t a s O u r c e s: Data on urinary 2,4-D excretion in general and target populations from recent pub-
lished studies are tabulated and the derivation of BE values for 2,4-D summarized. 
Da t a synthesis: The biomonitoring data indicate margins of safety (ratio of BE value to biomarker 
concentration) of approximately 200 at the central tendency and 50 at the extremes in the general 
population. Median exposures for applicators and their family members during periods of use 
appear to be well within acute exposure guidance values. 
cO n c l u s i O n s: Biomonitoring data from these studies indicate that current exposures to 2,4-D 
are below applicable exposure guidance values. This review demonstrates the value of biomonitor-
ing data in assessing population exposures in the context of existing risk assessments using the BE 
approach. Risk managers can use this approach to integrate the available biomonitoring data into an 
overall assessment of current risk management practices for 2,4-D.
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Alexander BH, et al. (2007) reported 
urinary 2,4-D data from the Farm Family 
Exposure Study. Participants in the study 
included 34 farmers in Minnesota and South 
Carolina who were licensed applicators and 
their spouses and children (n = 53) living on 
the farm property. Participants collected 24-hr 
urine samples the day before, the day of, and for 
3 days after application of 2,4-D on their farms 
during the 2000 or 2001 growing season.
Curwin et al. (2005) measured urinary 
2,4-D concentrations in 16 farmers 1–5 days 
after their application of 2,4-D on the farm 
during the spring and summer of 2001. The 
evening and the following first morning urine 
samples were composited.
The Pesticide Exposure Assessment Study 
measured the extent to which agricultural pes-
ticide applicators and their families in Ontario, 
Canada, are exposed to pesticides during nor-
mal handling practices (Arbuckle and Ritter 
2005; Arbuckle et al. 2002, 2004). Farmers 
from the previously conducted Ontario Farm 
Family Health Study (Arbuckle et al. 1999) 
that had reported using phenoxyacetic acid her-
bicides were telephoned in early 1996 to deter-
mine their eligibility for the Pesticide Exposure 
Assessment Study. To be eligible, the farmer 
had to a) be planning to use 2,4-D or (4-chloro- 
2-methylphenoxy)acetic acid (MCPA) in the 
coming growing season, b) be the individual 
who would be handling the herbicides on the 
farm, c) have his or her home on the farm 
property, and d) be currently living with his or 
her spouse. A total of 126 families provided a 
spot urine sample before handling either 2,4-D 
or MCPA and then provided two consecutive 
24-hr samples after use of the herbicide. All 
samples were collected in 1996.
The Agricultural Health Study (AHS)/
Pesticide Exposure Study (PES) was designed 
to evaluate exposure to 2,4-D and chlorpyrifos 
in a subset of individuals enrolled in the AHS, 
which is a large, prospective epidemiologic 
study of pesticide applicators and their spouses 
in Iowa and North Carolina designed to assess 
the relationships between agricultural exposures 
and disease. Participants in the AHS were con-
tacted randomly and surveyed to ascertain their 
planned use of the 2,4-D and chlorpyrifos, and 
then a subset of participants were enrolled in the 
PES (Thomas et al. 2009). Urinary samples were 
collected during 2001 and 2002 and included a 
preapplication first morning void sample, as well 
as a 24-hr sample starting the day of application 
(day 1) and, optionally, for days 2–5 as well.
Descriptions of the institutional review 
board approvals and informed consent infor-
mation for each of these studies are presented 
in the cited publications.
RfDs and biomonitoring equivalents. 
The U.S. EPA recently conducted a review of 
2,4-D and adopted both a chronic oral RfD 
as well as acute RfDs (applicable to single-day 
exposures) for this herbicide (U.S. EPA 2004). 
Table 1 summarizes the derivations of the BE 
values associated with the RfD values. BEs are 
defined as the concentration of a chemical or 
its metabolite in a human biological medium 
(usually blood or urine) that is consistent with 
existing exposure guidance values. BE values 
are screening values corresponding to existing 
risk assessments and not intended for use as 
definitive measures of risk for individuals. A 
full description of the BE approach and appli-
cation is beyond the scope of this review but is 
presented elsewhere (Hays and Aylward 2009; 
Hays et al. 2007, 2008).
The pharmacokinetics of 2,4-D have been 
studied in two sets of human volunteers (Kohli 
et al. 1974; Sauerhoff et al. 1977). Both studies 
found that 2,4-D is eliminated in urine either 
as the unchanged parent compound (80–95%) 
or as a conjugate, with urinary half-lives on the 
order of 1 day. There was no evidence of oxi-
dative metabolism, consistent with data from 
other mammalian species (Timchalk 2004). 
Based on these pharmacokinetic data, continu-
ing exposure for more than 1 week of expo-
sure would result in a steady state in which 
the amount excreted daily in urine would 
be approximately equivalent to the amount 
absorbed each day.
Because 2,4-D is excreted as the parent com-
pound in urine, most biomonitoring evaluations 
of exposure to 2,4-D have relied on measure-
ments (quantifying both free and conjugated 
parent compound) in urine samples (CDC 
2005; Knopp 1994; Knopp and Glass 1991), 
although a few kinetic studies have also exam-
ined plasma concentrations of 2,4-D in humans 
and animals (Kohli et al. 1974; Saghir et al. 
2006; Sauerhoff et al. 1977; van Ravenzwaay 
et al. 2003). The relative ease of collection of 
urine samples compared with blood samples 
contributes to this choice. From a toxicologic 
point of view, plasma concentrations of 2,4-D 
are probably more informative for predicting 
target tissue concentrations and responses (e.g., 
neurotoxic responses). This would be particu-
larly true under conditions of episodic, higher-
level exposures. However, under conditions of 
chronic, low-level exposures, urinary excretion 
rates of 2,4-D should be specific and quantita-
tively relevant in a framework of a mass-balance 
assessment. That is, under exposure conditions 
that approximate steady-state conditions [con-
sistent with the definition of chronic RfDs and 
related exposure guidance values; see, e.g., the 
definition of RfD provided under the U.S. EPA 
Integrated Risk Information System program 
(U.S. EPA 2009)], daily urinary excretion of 
2,4-D should equal daily intake.
The straightforward elimination kinetics 
of 2,4-D (as parent compound or conjugate in 
urine with essentially no oxidative metabolism) 
and the lack of direct relationship between uri-
nary concentration and critical internal dose 
metrics suggest a simple mass-balance approach 
Table 1. RfDs established by the U.S. EPA (2004) for 2,4-D and derivation of corresponding BE values. 
RfD
Acute
Reference value Chronic Females of reproductive age Other general population Occupational exposurea
Underlying study type Rat chronic dietary bioassay Rat oral gavage,  
gestational days 6–15
Rat acute gavage Rat chronic dietary bioassay
End point Decreased body weight gain and food 
consumption, alterations in hematology 
and clinical chemistry parameters, 
increased thyroid weights, and 
decreased testes and ovarian weights
Skeletal variations and 
malformations
Gait abnormalities Same as for chronic RfD
POD (NOAEL) (mg/kg-day) 5 25 67 5
Interspecies UF 10 10 10 10
Human equivalent POD (mg/kg-day) 0.5 2.5 6.7 0.5
BEPOD (urinary 2,4-D) 20,000 µg/L (30,000 µg/g cr) 40,000 µg/L (70,000 µg/g cr) 100,000 µg/L (200,000 µg/g cr) 20,000 µg/L (30,000 µg/g cr)
Intraspecies UF 10 10 10 10
Database UFb 10 10 10 NA
BERfD (urinary 2,4-D) 200 µg/L (300 µg/g cr) 400 µg/L (700 µg/g cr) 1,000 µg/L (2.000 µg/g cr) 2,000 µg/L (3,000 µg/g cr)
Abbreviations: cr, creatinine; NA, not applicable; NOAEL, no obseverd adverse effects level; POD, point of departure; UF, uncertainty factor. Details of the derivation are presented by 
Aylward and Hays (2008).
aDerivation based on U.S. EPA (2004) memorandum indicating a) POD same as for general population chronic RfD, and b) desired margin of exposure (ratio between POD and exposure 
level) of 100, based on UFs of 10 each for inter- and intraspecies variation. bUF applied to account for the lack of a developmental neurotoxicity study and the need for a repeated two-
generation bioassay with a focus on thyroid and immunotoxicity end points. 2,4-D biomonitoring data review
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for derivation of BE values for urinary 2,4-D 
consistent with chronic exposure at the chronic 
RfD. The process of deriving the BEPOD and 
BERfD values for 2,4-D is detailed by Aylward 
and Hays (2008) and summarized below and 
in Table 1.
The point of departure (POD) for the U.S. 
EPA chronic RfD is a no observed adverse 
effect level (NOAEL) of 5 mg/kg-day in rats 
fed 2,4-D chronically in the diet. Applying 
an uncertainty factor (UF) of 10 for interspe-
cies variation, the human equivalent POD is 
0.5 mg/kg-day. Calculating the average concen-
tration of 2,4-D in urine in humans associated 
with this chronic daily dose (after application 
of the interspecies UF) yields the BEPOD. The 
daily mass intake at the human equivalent 
POD was estimated for a variety of child and 
adult body weights. Estimated distributions of 
daily creatinine excretion or urinary volume as a 
function of sex, age, and body size were used in 
a Monte Carlo analysis to estimate a distribu-
tion of creatinine-adjusted urinary 2,4-D con-
centrations for various age and sex categories 
[methods are described in detail by Aylward 
and Hays (2008)]. The average of median esti-
mated creatinine-adjusted 2,4-D concentra-
tion consistent with chronic exposure at the 
human-equivalent POD (BEPOD) for 2,4-D 
for adults (males and females) is approximately 
20,000 µg/L or 30,000 µg/g creatinine. These 
values were consistent with the range of median 
values identified in the simulations for children 
of various ages. Concentrations at the 95th per-
centiles of the estimated distributions were gen-
erally within a factor of 2 of the median values.
The BE associated with the chronic RfD 
was derived by dividing the BEPOD, which 
reflects the interspecies UF of 10, by the UF of 
10 for intraspecies variation and the UF of 10 
applied by U.S. EPA for database uncertain-
ties (for a total composite UF from the animal 
POD of 1,000 applied to the animal NOAEL 
POD). BE values corresponding to the acute 
RfDs were derived in a similar fashion, except 
that steady state was not assumed. Based on the 
urinary elimination half-life of approximately 
1 day, an assumption was made that one-half of 
the intake dose at the human equivalent POD 
for the acute RfD values would be eliminated 
in the first 24 hr after exposures. Average uri-
nary 2,4-D concentrations (both absolute and 
creatinine adjusted) corresponding to one-half 
the human equivalent POD doses were esti-
mated, and the intraspecies and database UFs 
were then applied to obtain the BERfD_acute 
values. These BE values are appropriate for use 
when the exposure is short term and episodic 
and the timing of the sample collection com-
pared with exposure is known. Table 1 sum-
marizes the derivation and resulting values.
Results
Table 2 summarizes urinary 2,4-D concentra-
tions measured in studies of general popula-
tion groups (CDC 2005; Morgan et al. 2008). 
Exposure pathways for persons in the general 
population may include ingestion of residues 
in food products, inhalation, and direct contact 
with dust (Morgan et al. 2004, 2008). Figure 1 
presents the measured urinary concentrations in 
the context of the appropriate BE values based 
on the U.S. EPA chronic RfD. The urinary lev-
els of 2,4-D observed in the general population 
samples are far below the BE value correspond-
ing to the U.S. EPA chronic RfD, with median 
and upper bound measured concentrations 
more than 100- and 50-fold below the BERfD.
Table 3 summarizes the corresponding 
data for farmers and members of their families 
obtained in the days immediately after applica-
tion of 2,4-D. Exposure pathways for non-
applicators on the farm may include secondary 
exposure to treated fields, farm machinery, or 
the applicator, and drift of herbicide during 
application with resulting inhalation, dermal, 
and oral exposure after contact with residues on 
surfaces in the home. Urinary concentrations 
collected from farm family members in the day 
or days immediately after application of 2,4-D 
fell below the applicable acute BE values.
Figure 2 presents measured urinary concen-
trations in farmers involved in application of 
2,4-D in the context of BE values corresponding 
to the U.S. EPA occupational exposure guidance 
values. Again, the data suggest an overall margin 
of safety, with median or geometric mean lev-
els in farmers involved in application of 2,4-D 
more than 25-fold below the occupational BE 
target value. However, some individuals had sin-
gle spot urinary concentrations that approached 
the occupational BE target value. The high-
est urinary level of 2,4-D reported in Thomas 
et al. (2009) on days 1–5 after application was 
2,500 µg/L, in excess of the occupational BE 
value of 2,000 µg/L (data not shown). However, 
all other reported occupational measurements 
were below the occupational BE.
Discussion
Available biomonitoring data for 2,4-D in 
both the general and agricultural populations 
indicate that current uses and practices sug-
gest exposures that are below the acceptable 
exposures identified by the U.S. EPA. A “mar-
gin of safety” is the ratio between the expo-
sure guidance value and measured exposure. 
In this analysis, the exposure guidance value 
(RfD) was converted to a BERfD value for com-
parison with the measured biomarker concen-
trations. General population values indicate a 
margin of safety compared with the BERfD of 
approximately 200 at the central tendency and 
> 50 at the upper percentiles of exposure. In 
turn, the BERfD is 100-fold below the BEPOD, 
which is the biomarker concentration associated 
with chronic intake in humans at the POD 
Table 2. Urinary biomonitoring data for samples from the general U.S. population.
Percentile
Study (n) 
Age group (years), 
population Sample description
µg/L µg/g cr
50th 95th 50th 95th
NHANES, 2001–2002 (CDC 2005) 
546 6–11, USA Spot < LODa 1.55 < LOD 1.40
797 12–19, USA Spot < LOD 1.24 < LOD 0.662
1,070 20–59, USA Spot < LOD 1.27 < LOD 1.04
2,413 All, 6–59, USA Spot < LOD 1.27 < LOD 1.08
Morgan et al. (2008)
66 2–5, NC 48-hr composites 0.5 1.9 1.0b 3.4b
69 2–5, OH 48-hr composites 1.2 4.3 1.5c 5.1c
66 20–44, NC 48-hr composites 0.7 2.8 0.6b 2.3b
69 19–49, OH 48-hr composites 0.7 3.3 0.5c 3.3c
LOD, limit of detection.
aLOD for NHANES 2001–2002 was 0.2 µg/L. bn = 55. cn = 59.
Figure 1. Urinary 2,4-D concentrations (µg/L) in gen-
eral population studies presented in the context of 
the BE value corresponding to the U.S. EPA RfD for 
general population chronic exposures. The symbol 
for data from NHANES (CDC 2005) represents the 
95th percentile for all tested participants (median 
values were below the LOD; see Table 2). The 
symbols for data from Morgan et al. (2008) (in key, 
Morgan) represent the median values for the chil-
dren and adults from two states; bars extend to the 
95th percentile for each group. The shaded regions 
represent concentration ranges associated with 
low, medium, and high priority for risk assessment 
follow-up based on the criteria described in the BE 
communications guidelines (LaKind et al. 2008).
Increasing priority for
risk assessment follow-up
100,000
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extrapolated from animals to humans. The con-
clusion of a substantial margin of safety holds 
whether comparisons are made using volume 
or creatinine-adjusted concentrations. Median 
or average urinary 2,4-D concentrations for 
applicators are consistently below the BE values 
associated with occupational exposure targets 
set by the U.S. EPA (2004); however, evidence 
exists for exceptions near the occupational 
BE target value in a few individuals from the 
studied occupationally exposed populations. 
Biomonitoring data for spouses and children 
of applicators on the day after use of 2,4-D also 
are less than the BE values associated with gen-
eral population acute exposure RfDs set by the 
U.S. EPA (2004).
Other studies have reported related 
biomonitoring data. Arcury et al. (2007) stud-
ied children from North Carolina farm worker 
families in 2004. Multiple pesticides (or metab-
olites) were measured in urine samples from 
these children (1–6 years of age). The median 
2,4-D concentration was below the limit of 
detection (LOD) of 0.2 µg/L (42% of the 60 
sampled children had detectable concentrations 
of 2,4-D, but the range of detected concentra-
tions was not reported). Garry et al. (2001) 
measured urinary 2,4-D in small numbers of 
forestry applicators who used a variety of meth-
ods to apply the herbicide. Backpack sprayers 
had the highest measured urinary concentra-
tions during time periods of use, with a median 
of 160 µg/L and a range up to 1,700 µg/L (n = 
7). Other modes of application such as use of 
boom sprayers or aerial applications resulted in 
lower urinary 2,4-D concentrations, with all 
measured values < 500 µg/L for boom sprayers 
and < 100 µg/L for other modes. These values 
are consistent with the concentrations observed 
in farm applicators from the Alexander BH, 
et al. (2007) study and are also below the occu-
pational BERfD presented in Table 1.
The evaluation presented here is based 
on BE values derived from the U.S. EPA 
risk assessment of 2,4-D (U.S. EPA 2004). 
However, the Canadian PMRA has also 
recently estimated acceptable daily exposures to 
2,4-D (PMRA 2007). The derived acute and 
chronic RfDs are based on the same under-
lying data as used by the U.S. EPA, with sim-
ilar or identical choices of POD. However, 
the PMRA assessment generally applied total 
UFs approximately 3-fold lower than those 
applied by the U.S. EPA, resulting in expo-
sure estimates that are approximately 3-fold 
greater than those set by the U.S. EPA. Thus, 
the BEPOD values associated with the PMRA 
risk assessment would be essentially identical 
to those for the corresponding U.S. EPA expo-
sure guidance values. Although BE values were 
not specifically derived based on the PMRA 
assessments, corresponding urinary BE values 
would be approximately 3-fold higher than 
those derived based on the U.S. EPA RfDs. BE 
values corresponding to the PMRA acute RfD 
values for acute exposure in the general popula-
tion and in females of reproductive age equal 
to 1,000 and 4,000 µg/L, respectively (2,000 
and 7,000 µg/g creatinine). The BE value cor-
responding to the PMRA acceptable daily 
intake for chronic exposure would be 700 µg/L 
(1,000 µg/g creatinine). Thus, reliance on the 
PMRA risk assessment does not change the 
overall conclusion of a substantial margin of 
safety under the various exposure scenarios.
Uncertainties and limitations. BE values 
are derived based on expected average con-
centrations (either volume based or creatinine 
adjusted) in urine under conditions consistent 
with the underlying exposure guidance value 
(chronic or acute exposure conditions). Some 
variability in concentration is expected because 
of use of spot urine samples, interindividual 
variability in creatinine excretion rates, and 
variability in urinary volume due to hydration 
status. Morgan et al. (2004, 2008) investigated 
the variability of 2,4-D concentrations among 
spot urine samples (i.e., first morning void, 
after lunch, and before bedtime) collected over 
the course of 48 hr from 28 adults and 28 chil-
dren. The maximum measured spot urine value 
was within a factor of 3 of the mean value in 
53 of the 56 individuals, consistent with pre-
vious assessments of variability among spot 
samples (e.g., Scher et al. 2007).
2,4-D is relatively short-lived, with a uri-
nary half-life on the order of 1 day, so for an 
individual in the general population, a single 
measurement does not characterize long-term 
exposure. However, the NHANES urinary 
data for 2,4-D are representative of the U.S. 
population, and samples were collected at vari-
ous times through the year. NHANES data 
would be expected to capture indications of 
higher exposures if they were occurring with 
any frequency, unless such variations were 
highly seasonal and geographically isolated. 
Urinary concentration data from Morgan 
et al. (2004, 2008) collected from two differ-
ent geographical regions of the United States 
(North Carolina and Ohio) over the course of 
a year suggest somewhat higher exposures than 
reflected in the NHANES data set, but both 
sets indicate general population exposures far 
below health-based exposure guidance values.
A notable deficit in the available data for 
the general population pertains to residen-
tial uses of 2,4-D. Unlike exposures to 2,4-D 
users in agricultural populations, systematic 
Table 3. Concentrations of 2,4-D measured in urine collected after acute exposure due to agricultural use 
of 2,4-D.
Median (range)
Group, n µg/L  µg/g cr Sample type Study
Applicators
34 73.1 (1.5–1,856) 45.8 (1.1–533.8) 24 hr Alexander BH, et al. 2007
43 6.0 (0.5–410.0) NR 24 hr Arbuckle et al. 2002
16 13a (NR) NR Composite of 
evening and 
following morning 
spot samples
Curwin et al. 2005
28 26b (2.2–1,000) NR 24 hr Thomas et al. 2009
Spousesc
34 1.2 (0.5–20) 1.1 (0.2–13.1) 24 hr Alexander BH, et al. 2007
43 < LODd (< LOD to 61) NR 24 hr Arbuckle and Ritter 2005
Children ages 4–17 years
52 2.9 (0.5–640.4) 2.3 (0.3–660.2) 24 hr Alexander BH, et al. 2007
Children ages 3–18 years
91 < LODd (< LOD to 12) NR 24 hr Arbuckle et al. 2004
NR, not reported. Concentrations reported are 2,4-D in urine samples collected 1 day after application of 2,4-D on farms 
in applicators (Alexander BH, et al. 2007; Arbuckle et al. 2002; Thomas et al. 2009) and family members (spouses and 
children; Alexander BH, et al. 2007; Arbuckle et al. 2004) or in applicators 1–5 days after application (Curwin et al. 2005).
aGeometric mean for farmers who reported spraying 2,4-D themselves in the previous 1–5 days. bGeometric mean. cAll 
spouses were female, and all applicators were male. dLOD = 1 µg/L.
Figure 2. Urinary 2,4-D concentrations (µg/L) in 
applicators on the day after application of 2,4-D 
presented in the context of the human-  equivalent 
BEPOD and target BE values associated with the 
occupational risk assessment (U.S. EPA 2004) 
(see Table 1). Symbols represent the median (or, 
in the case of Curwin et al. 2005 and Thomas et al. 
2009, the geometric mean), and the bars extend to 
the maximum measured value in each study (not 
reported for Curwin et al. 2005). For description of 
shaded regions, see Figure 1 legend.
Increasing priority for
risk assessment follow-up
100,000
10,000
1,000
100
10
1
BEPOD:
20,000 µg/L
BE:
2,000 µg/L
High
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×
Curwin et al. 2005
Alexander et al. 2007
Arbuckle et al. 2002
Thomas et al. 2009 ×2,4-D biomonitoring data review
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evaluations of domestic use of the chemical are 
not available. These episodic exposures would 
not likely be captured in the NHANES (CDC 
2005) or Morgan et al. (2008) data. To the 
extent that domestic applications do not result 
in exposures greater than those resulting from 
agricultural applications, human exposures 
should be within the margin of safety dem-
onstrated by these existing study data. More 
research is needed to understand the patterns 
of domestic use of 2,4-D in residential settings 
and the resulting potential human exposures to 
this herbicide in the United States and Canada.
The RfD values derived by the U.S. EPA 
are based on noncancer end points. 2,4-D has 
also been assessed for potential carcinogenic 
effects. Non-Hodgkin lymphoma (NHL) was 
associated with herbicides and 2,4-D in a series 
of case–control studies initiated > 20 years 
ago (Hoar et al. 1986; Zahm et al. 1990). 
Subsequent case–control and cohort studies 
have not confirmed these early observations 
(Burns et al. 2001; De Roos et al. 2003; Hartge 
et al. 2005; Pearce 1989; Schroeder et al. 
2001; Woods et al. 1987). Recent reviews of 
NHL (Alexander DD, et al. 2007) and 2,4-D 
(Garabrant and Philbert 2002) have concluded 
that the epidemiologic evidence remains “scant” 
and unsupportive for this association.
BE values are screening values and are not 
intended for use as definitive measures of risk for 
individuals. They do not represent a bright line 
between safe and unsafe levels, but rather allow 
evaluation of biomonitoring data in a public 
health risk context consistent with the existing 
risk assessment for 2,4-D (LaKind et al. 2008). 
Biomarker concentrations below the BERfD indi-
cate a low priority for risk assessment   follow-up, 
whereas concentrations in excess of the BERfD 
but below the BEPOD indicate a medium pri-
ority for risk assessment follow-up. Values in 
excess of the BEPOD indicate a high priority 
for risk assessment follow-up. Risk assessment 
follow-up may include examination of the 
underlying risk assessment, exposure pathway 
investigations, or other risk management activi-
ties (LaKind et al. 2008). Acute RfDs and the 
corresponding BE values are targeted at isolated, 
single-day exposures and are appropriate for use 
in evaluating biomonitoring data only when 
there is specific knowledge of a potential acute 
exposure. The biomonitoring data reviewed here 
for both members of the general population and 
applicators generally falls into the range of low 
priority for risk assessment follow-up, accord-
ing to the guidelines for BE communication 
(LaKind et al. 2008).
Conclusions
Considerable population-level and microlevel 
data are now available regarding domestic and 
agricultural exposures to 2,4-D as measured 
by urinary 2,4-D excretion. These data suggest 
that current use patterns and risk management 
efforts by industry and government are likely 
keeping average exposure to 2,4-D for the gen-
eral population and in farm family members, 
and likely other persons potentially exposed 
from proximity to use of this herbicide, to lev-
els well below current noncancer reference val-
ues established both by the U.S. EPA’s Office 
of Pesticide Programs and by Canada’s PMRA.
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